Hypermethylated APC in serous carcinoma based on a meta-analysis of ovarian cancer.
BACKGROUND
The reduced expression of the Adenomatous polyposis coli (APC) gene, a tumor suppressor gene, through promoter hypermethylation has been reported to play a key role in the carcinogenesis. However, the correlation between APC promoter hypermethylation and ovarian cancer (OC) remains to be clarified.


METHODS
A comprehensive literature search was carried out in related research databases. The overall odds ratio (OR) and corresponding 95 % confidence interval (CI) were used to evaluate the effects of APC promoter hypermethylation on OC and clinicopathological characteristics.


RESULTS
Ultimately, 12 eligible studies were used in our study, including 806 OC samples, 429 normal controls, 109 benign lesions and 75 LMP samples. The pooled OR showed that APC promoter hypermethylation was significantly higher in OC than in normal and benign controls (OR = 6.18 and OR = 3.26, respectively). No significant correlation was observed between OC and low malignant potential (LMP) tumors (P = 0.436). In the comparison of OC and normal controls, subgroup analysis based on race showed that the overall OR of APC promoter hypermethylation was significant and similar in Asians and Caucasians (OR = 8.34 and OR = 5.39, respectively). A subgroup analysis based on sample type found that the pooled OR was significantly higher in blood than in tissue (OR = 18.71 and OR = 5.74, respectively). A significant association was not observed between APC promoter hypermethylation and tumor grade or tumor stage. The pooled OR indicated that APC promoter hypermethylation was significantly lower in serous carcinoma than in non-serous carcinoma (OR = 0.56, P = 0.02). No obvious publication bias was detected by Egger's test (all P > 0.05).


CONCLUSIONS
APC promoter hypermethylation may be linked to the increased risk of OC. It was associated with histological type, but not with tumor grade or tumor stage. Moreover, hypermethylated APC may be a noninvasive biomarker using blood samples. Future studies are required to validate these results.
Obstetrics and Gynecology Department, The No. 2 Hospital of Yinzhou, Ningbo, 315040, Zhejiang, China.
Chunyan
C
Shen
Obstetrics and Gynecology Department, The No. 2 Hospital of Yinzhou, Ningbo, 315040, Zhejiang, China. shengqifangnb@163.com.
Qifang
Q
Sheng
Obstetrics and Gynecology Department, The No. 2 Hospital of Yinzhou, Ningbo, 315040, Zhejiang, China. 276802346@qq.com.
Xiaojie
X
Zhang
Obstetrics and Gynecology Department, The No. 2 Hospital of Yinzhou, Ningbo, 315040, Zhejiang, China.
Yuling
Y
Fu
Obstetrics and Gynecology Department, The No. 2 Hospital of Yinzhou, Ningbo, 315040, Zhejiang, China.
Kemiao
K
Zhu
APC; Biomarker; Hypermethylation; Ovarian cancer; Serous carcinoma
Genet Res Int. 2013;2013:317569
24455281
Epigenomics. 2014;6(4):415-26
25333850
J Biomed Opt. 2012 Aug;17(8):081412-1
23224173
Arch Toxicol. 2014 May;88(5):1043-67
24691704
Gynecol Oncol. 2013 Jul;130(1):132-9
23623832
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2621-8
25703813
Cancer Res. 2015 Oct 15;75(20):4252-9
26392073
J Cell Sci. 2013 Feb 15;126(Pt 4):873-7
23589686
Stat Med. 1996 Jun 30;15(12):1237-48; discussion 1249-52
8817798
World J Biol Chem. 2015 Nov 26;6(4):333-45
26629316
Nihon Rinsho. 2015 Aug;73(8):1263-7
26281676
J Cancer Res Clin Oncol. 2007 May;133(5):331-41
17177027
Int J Epidemiol. 2010 Jun;39(3):932; author reply 933
19349478
Cancer Res. 2004 Sep 15;64(18):6476-81
15374957
Cell Oncol (Dordr). 2012 Dec;35(6):473-9
23055343
Eur J Clin Invest. 2010 Apr;40(4):310-8
20486992
PLoS One. 2016 Mar 16;11(3):e0151590
26981633
BMC Cancer. 2015 Oct 09;15:669
26452468
Biochem Med (Zagreb). 2015 Jun 05;25(2):161-76
26110029
BMJ. 2003 Sep 6;327(7414):557-60
12958120
Clin Cancer Res. 2005 Aug 1;11(15):5365-9
16061849
Nat Cell Biol. 2001 Apr;3(4):433-8
11283620
JAMA. 2006 Feb 8;295(6):676-80
16467236
Mol Cancer. 2007 Jul 10;6:45
17623056
Methods Mol Biol. 2012;863:3-14
22359284
Asian Pac J Cancer Prev. 2014;15(6):2719-25
24761891
Int J Mol Sci. 2015 Jan 22;16(2):2472-96
25622259
Curr Top Microbiol Immunol. 2000;249:35-54
10802937
J Exp Clin Cancer Res. 2015 Oct 28;34:131
26511139
Clin Cancer Res. 2002 Nov;8(11):3324-31
12429618
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
26742998
Med Klin (Munich). 2003 Dec 15;98(12):776-82
14685680
Mutat Res. 2015 Aug;778:46-51
26073472
PLoS One. 2013 Sep 27;8(9):e70878
24086249
Sci Rep. 2015 Mar 10;5:8897
25754026
Pathol Oncol Res. 2008 Mar;14(1):51-6
18369740
Ann Oncol. 2013 Dec;24 Suppl 10:x16-21
24265397